A Comparative, Double-blind, Randomised Trial of a New Second Generation LMWH (Bemiparin) and UFH in the Prevention of Post-operative Venous Thromboembolism

Summary

A randomised, prospective, double-blind trial was performed, to compare the safety and efficacy of a new low-molecular-weight heparin (LMWH) Bemiparin and standard unfractionated heparin (UFH), for the prophylaxis of postoperative venous thromboembolism. 300 patients scheduled to undergo elective hip arthroplasty were included. The principal outcome measures were the incidence of thromboembolic events and bleeding complications. 149 patients received 3,500 anti-Xa IU of bemiparin plus a placebo injection daily and 149 patients received 5,000 IU of UFH twice a day.

The two groups were similar with respect to factors likely to affect the risk of developing post-operative venous thromboembolism (VTE) and risk of bleeding events. During the post-operative period, 34 patients developed VTE complications; 9 (7.2%) in the bemiparin group and 25 (18.7%) in the UFH group. VTE in the two groups was statistically significant (OR of 2.96; 95% CI 1.32-6.62 and p = 0.01).

There were no significant differences in the frequency of bleeding complications: major bleeding requiring discontinuation of prophylaxis, (OR 1.21; 95% CI 0.36-4.05; p = 1.00), the measured median operative blood loss (p = 0.77) or the median postoperative drain loss (p = 0.97), and the number of patients who developed wound haematoma (OR 0.87; 95% CI 0.31-2.46; p = 1.00).

A comparison of coagulation parameters on the preoperative day with post-operative day 2 ± 1, day 6 ± 1 and day of discharge showed a significantly higher AT concentration, anti-factor Xa activity and TFPI levels in the bemiparin group when compared with UFH.

This study demonstrates that bemiparin, in a single daily subcutaneous dose of 3,500 anti-Xa IU in high risk patients undergoing hip arthroplasty is more effective than UFH administered twice daily at a dose of 5,000 IU in the prevention of postoperative VTE. Both agents are equally safe.

List of participants, their affiliations and current addresses are listed in the appendix on p. 528

Keywords

Heparin - prevention of venous thromboembolism

• References

• 1 Leizorovicz A, Haugh MC, Chapuis F, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913-20.
• 2 Kakkar VV. International multicentre trial: Prevention of postoperative pulmonary embolism by low doses of heparin. Lancet 1975; 02: 45-51.
• 3 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. Brit Med J 1982; 284: 375-9.
• 4 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the haemorrhagic and anti-thrombotic properties of low molecular weight heparins and heparin in rabbits. Blood 1982; 59 (06) 1239-45.
• 5 Hemker HC, Beguin S. Mode of action of heparin and related drugs Semin. Thromb Haemost 1991; 17 (Suppl. 01) 29-34.
• 6 Human Blood Coagulation, Haemostasis and Thrombosis. Ed. Rosemary Briggs. Pub. Blackwell Scientific Pub; Oxford: 1975
• 7 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10 (03) 399-410.
• 8 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50 (06) 803-13.
• 9 Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg Is there a “high risk” group. Am J Surg 1970; 120: 527-30.
• 10 Kakkar VV, Cohen AT, Edmondson RA. et al. Low molecular weight heparin versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-65.
• 11 Bara L, Leizorovicz A, Picolet H, Samama M. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post surgical patients treated with either logiparin (LMWH) or unfractionated heparin Postsurgery Logiparin Study Group. Thromb Res 1992; 65 4-5 641-50.
• 12 Thomas DP, Morton RE, Gray E, Barrowcliffe TW. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin and a pentasaccharide fragment in an animal model. Thromb Haemost 1989; 61 (02) 204-7.
• 13 Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-Xa level and clinical outcome in patients receiving enoxaparine (LMWH) to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989; 62 (03) 940-4.
• 14 Dahl OE, Aspelin T, Lyberg T. The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Blood Coag Fibrin 1995; 06: 709-17.
• 15 Dahl OE, Aspelin T, Arnesen H, Seljeflot I, Kierrulf P, Ruyter R, Lyberg T. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995; 80: 299-306.
• 16 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin Overview of results of randomised trials in general, orthopaedic and urological surgery. New Eng J Med 1988; 318: 1162-73.
• 17 Hull RD, Brant TF, Pineo GE. et al. Pre-operative versus postoperative initiation of low molecular weight heparin prophylaxis against thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999; 159 (02) 137-41.
• 18 Lumpkin MM. FDA alert. FDA public health advisory. Anesthesiology 1998; 88 (02) 27A-8A.
• 19 Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anaesthetic management. Anesth Analg 1997; 85: 874-85.
• 20 Dahlagren N, Tombrandt K. Neurological complications after anaesthesia: a follow up of 18,000 spinal and epidural anaesthetics performed over three years. Acta Anaesthesiol Scand 1995; 39: 872-80.
• 21 Bergqvist D, Linblad B, Matzsch T. Low molecular weight heparin for thromboprophylaxis and epidural/spinal anaesthesia – is there a risk?. Acta Anesthesiol Scand 1992; 36: 605-9.
• 22 Lund PC. Peridural anaesthesia Springfield Illinois. Charles C. Thomas. 1966
• 23 Tryba M. Epidural regional anaesthesia and low molecular weight heparin Pro. Anesthesiol. Intensivmed. Notfallmed Schmerzther 1993; 28: 179-81.
• 24 Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinalepidural anesthesia. Anesth Analg 1994; 79: 1165-77.
• 25 Trowlidge A, Boese LK, Woodruff B, Brindley HH, Lowry WE, Spiro TE. Incidence of post-hospitalization proximal deep venous thrombosis after total hip arthroplasty: a pilot study. Clin Orthop 1994; 299: 203-8.
• 26 Stamatakis JD, Kakkar VV, Sagar S, Lawrence D, Nairn D, Bentley PG. Femoral vein thrombosis and total hip replacement. BMJ 1977; 02: 223-5.
• 27 Dahl OE, Molnar I, Vinje A, Ro JS. et al. Studies on coagulation, fibrinolysis, kallikrein-kinin and complement activation in systemic and pulmonary circulation during hip arthroplasty with acrylic cement. Thromb Res 1988; 50: 875-84.
• 28 Dahl OE, Anderson G, Aspelin T. et al. Prolonged thromboprophylaxis following hip replacement surgery Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin. Thromb Haemost 1997; 77 (01) 26-61.
• 29 Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo HPBro. et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty – the Danish prolonged prophylaxis (DaPP) study. Thromb Res 1998; 89 (06) 281-7.
• 30 Bergqvist D, Benoni G, Bjorgell O. Fredin et al. Low molecular weight heparin (Enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Eng J Med 1996; 335: 696-700.
• 31 Planes A, Vochello M, Darmon JY. et al. Risk of deep vein thrombosis after hospital discharge in patients having undergone total hip replacement: double-blinded randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.